Connect with us
2022 Green Living Expo
The Northern Rivers Times
The Northern Rivers Times | NSW Northern Rivers News
2022 Green Living Expo NEWSLETTER Horizontal
Facebook and Website Banner 81
The Northern Rivers Times | NSW Northern Rivers News
previous arrow
next arrow

COVID-19 Northern Rivers News

NSW latest Covid update as at 30 December

Published

on

NSW latest Covid update as at 30 December

To Tuesday 28 December 2021 across NSW, 95 per cent of people aged 16 and over have received a first dose of a COVID-19 vaccine, and 93.5 per cent have received two doses.

Of the people aged 12 to 15, 81.5 per cent have received a first dose of COVID-19 vaccine, and 78.1 per cent have received two doses.

The total number of vaccines administered in NSW is now 13,602,370 with 4,355,921 administered by NSW Health to 8pm last night and 9,246,449 administered by the GP network, pharmacies and other providers to 11.59pm on Tuesday 28 December 2021.

NSW Health encourages everyone who is eligible to book into a NSW Health vaccination clinic or another provider without delay through the COVID-19 vaccine clinic finder.

Booster doses of COVID-19 vaccine are now available for people aged 18 and over. We urge people to get their booster dose as soon as they are eligible, to best protect yourself, your loved ones and the community from the ongoing transmission of COVID-19. We also strongly recommend that people aged 12 years and over who are severely immunocompromised have a third primary dose of vaccine from two months after their second dose.

Sadly, NSW Health is today reporting the death of a woman in her 70s from the Central Coast who died at Wyong Hospital. She was a resident of the Hakea Grove Aged Care facility, where she acquired her infection. She was not vaccinated and had underlying health conditions. NSW Health expresses its sincere condolences to her loved ones.

There are currently 746 COVID-19 cases admitted to hospital, with 63 people in intensive care, 24 of whom require ventilation.

There were 97,201 COVID-19 tests reported to 8pm last night, compared with the previous day’s total of 157,758.

NSW recorded 12,226 new cases of COVID-19 in the 24 hours to 8pm last night.

Forty-three COVID-19 cases have been excluded following further investigation, bringing the total number of cases in NSW since the beginning of the pandemic to 166,184.
Northern Rivers COVID Cases

 

 

 

 

 

 

Testing capacity in NSW is currently under enormous pressure and the only people getting a PCR (nose and throat swab) should be those who have COVID-19 symptoms; live in a household with a confirmed COVID-19-positive case; or have otherwise been advised by NSW Health to get tested.

This applies to people who are fully or partially vaccinated, as well as those not vaccinated.

Rapid antigen testing can be an additional precaution that you can take if you are planning to socialise with large groups of people, particularly indoors, or interacting with people who are elderly or have serious health conditions. Information on how to use rapid antigen tests is available on the NSW Government website.

Around a quarter of people exposed to COVID-19 may still develop their infection after seven days. For the subsequent seven-day period, they should exercise caution and avoid high-risk settings and large indoor gatherings, and use a rapid antigen test if coming into contact with vulnerable people.

Of the 12,226 cases reported to 8pm last night, 2,229 are from South Eastern Sydney Local Health District (LHD), 2,085 are from South Western Sydney LHD, 2,042 are from Western Sydney LHD, 1,767 are from Sydney LHD, 1,310 are from Northern Sydney LHD, 708 are from Hunter New England LHD, 612 are from Nepean Blue Mountains LHD, 291 are from Central Coast LHD, 247 are from Illawarra Shoalhaven LHD, 244 are from Northern NSW LHD, 120 are from Mid North Coast LHD, 107 are from Southern NSW LHD, 73 are from Western NSW LHD, 72 are from Murrumbidgee LHD, eight are from Far West LHD, three are in correctional settings, and 308 are yet to be assigned to an LHD.

If you are directed to get tested for COVID‑19 or self-isolate at any time, you must follow the self-isolation rules.

If you have any COVID-19 symptoms, no matter how mild, get tested immediately and self-isolate until you receive a negative test result.

There are more than 450 COVID-19 testing locations across NSW, many of which are open seven days a week. To find your nearest clinic visit COVID-19 clinics or contact your GP.
COVID-19 vaccination update
COVID-19 vaccination update

 

 

 

* to 11.59pm 28 December 2021

** Please note: The 12 to 15-year-old vaccination rate has dropped slightly as unvaccinated children move into the 12 to 15-year-old bracket and 16-year-olds move into the 16+ age bracket. This results in small movements in age cohorts.**COVID-19 vaccination doses administered by NSW Health

* notified from 8pm 28 December 2021 to 8pm 29 December 2021

COVID-19 Northern Rivers News

AUS passes 2m Covid cases, hits 1-in-10 NSW & VIC residents

Published

on

By

AUS passes 2m Covid cases, hits 1-in-10 NSW & VIC resident

AUS passes 2m Covid cases, hits 1-in-10 NSW & VIC residents

Australia has just passed two million official Covid cases today (Thursday), with one-in-10 New South Wales and Victorian residents now living with a diagnosis leading into the upcoming Federal Election, the latest VaxEnomicTM Forecaster from C-suite strategy group Provocate reveals.

Provocate Managing Director Troy Bilsborough said it represented a doubling of cases in under two weeks since Provocate first revealed Australia had hit the one-million case mark last Monday (10 January 2022).

“It took Australia two years to reach its first one million Covid cases and under two weeks to reach its second,” said Mr Bilsborough – a former senior advisor to Federal Health, Aged Care and Child Care Ministers.

“Healthcare influenced more votes than any other issue at the last Federal election and two million Australians now living with a Covid diagnosis will likely entrench that.

“This week’s negative polling on the Federal Government’s handling of the pandemic and economy continues to support our prediction that Covid and health will likely sway votes – and even the result – at May’s election.

“The arrival of a heavily-mutated variant like Omicron within five months of Delta also means there’s every chance Australia could be facing another outbreak from another new variant heading into the Federal Election campaign.”

“However, the biggest threat to business and voter confidence is not the virus itself, but politically-opposed state and Federal governments making decisions based on electionomics, not epidemiology or the economy.

It comes as top US Government Covid adviser Anthony Fauci also warned on Tuesday Omicron may not be the end of Covid with further mutations possible, supporting Provocate’s recent prediction Australia could be facing another virus variant in time for the next Federal election, slated for May 2022.

AUS passes 2m Covid cases, hits 1-in-10 NSW & VIC resident

AUS passes 2m Covid cases, hits 1-in-10 NSW & VIC resident

“The big unknown is whether Covid continues to matter when Australia is predicted to go to the polls in May – and whether opposition parties can continue to maintain voter dissatisfaction for that long.

“Much of this will hinge on how the longer-term impacts of Covid for the millions of Australians who now caught the virus, and how much onus attention medical, patient and worker representations place on having them recognised as chronic illness.”

About 90 per cent of total Australian cases have been recorded in the seven weeks since Omicron’s arrival in late November. That equates to an 800%+ increase in recorded cases in less than seven weeks, noting actual infections in the community were likely double or more that due to restricted testing options.

Provocate last week predicted the rapid transition from Covid as a public health and economic threat to a personal problem for millions of Australians would negatively impact voter views towards the Federal Government leading into the Election.

This was supported by this week’s Resolve Political Monitor, which showed since the May 2021 Federal Budget:

· a -22 point decline in the Federal Government’s lead on handling of Covid and the pandemic.

· a -13 point decline in the Federal Government’s lead on handling of economic management.

· a -10 point decline in the Federal Government’s lead on handling of health & aged care, with the Opposition now in front.

· a -5 point decline in the Federal Government’s primary vote, with the Opposition taking the lead for the first time during that period.

· A -16 point decline in the Federal Government’s lead on Preferred Prime Minister.

 

Figure 1 Source: Provocate analysis of ANU 'The 2019 Election Study'

Figure 1 Source: Provocate analysis of ANU ‘The 2019 Election Study’

Continue Reading

COVID-19 Northern Rivers News

TGA Approves Pfizer’s Novel COVID-19 Oral Treatment in Australia

Published

on

By

The NSW Northern Rivers Times COVID19 News Updates

TGA Approves Pfizer’s Novel COVID-19 Oral Treatment in Australia

• Therapeutic Goods Administration (TGA) approves PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for supply to Australia.

• PAXLOVID is the first oral treatment of its kind; it includes nirmatrelvir, a 3CL (or main) protease inhibitor that was specifically designed to combat SARS-CoV-2.

• Pfizer Australia has entered an agreement with the Australian Government to supply 500,000 treatment courses over 2022.

SYDNEY, AUSTRALIA, 20 January 2021 – Pfizer announced today that Australia’s Therapeutic Goods Administration (TGA) has granted provisional approval for the supply and use in Australia of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets. PAXLOVID has provisional approval for the treatment of coronavirus disease 2019 (COVID-19) in adults 18 years of age and older, who do not require initiation of supplemental oxygen due to COVID-19 and are at increased risk of progression to hospitalisation or death.

PAXLOVID is the first oral antiviral of its kind; it includes nirmatrelvir, a 3CL protease (also known as Main protease or Mpro) inhibitor that was specifically developed in Pfizer’s laboratories to combat SARS-CoV-2. Under this authorisation, PAXLOVID can be prescribed as an oral treatment to certain high-risk adults within the first 5 days of symptomatic infection, potentially helping patients avoid severe illness which can lead to hospitalisation or death.

“This milestone in Australia is an important moment in our continued fight against COVID-19, paving the way for use of PAXLOVID as cases continue to rise and we address the threat of a new variant of concern, Omicron,” said Anne Harris, Pfizer Australia and New Zealand Managing Director. “This at-oral therapy, developed to reduce hospitalisations and save lives, has the potential to transform COVID-19 treatment and help lessen the devastating impact of the virus that has now taken over 5 million lives globally”, Ms Harris said.

The TGA based its decision on positive results from the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) interim analysis, which enrolled non-hospitalised adults with confirmed COVID-19 who were at increased risk of progressing to severe illness. The data demonstrated an 89% reduction in risk of COVID-19-related hospitalisation or death from any cause in adults treated with PAXLOVID compared to placebo in those treated within three days of symptom onset, with no deaths in the treatment group. Similar results were seen in those treated within five days of symptom onset. Treatment-emergent adverse events were comparable between PAXLOVID (19%) and placebo (21%), most of which were mild in intensity. Pfizer recently announced that results from the final analysis of the primary endpoint from all patients enrolled in EPIC-HR were consistent with the interim analysis, confirming efficacy with a similar safety profile. Additional Phase 2/3 clinical trials are ongoing in adults at standard risk of progressing to severe illness, and in those who have been exposed to the virus through household contacts.

In October 2021, Pfizer announced an agreement with the Australian Government to supply 500,000 treatment courses of PAXLOVID over 2022. With the oral treatment now approved for supply and use by the TGA, Pfizer will begin delivering the first treatment courses from Q1 2022.

Continue Reading

COVID-19 Northern Rivers News

Under 12s to access protection against the worst of COVID from Monday 10 January

Published

on

By

Under 12s to access protection against the worst of COVID from Monday 10 January

Under 12s to access protection against the worst of COVID from Monday 10 January

• Pfizer vaccine available from Monday 10 January to children aged 5 to 11 years.
• Parents and guardians are encouraged to book through the Vaccine Clinic Finder.
• Vaccination protects our younger community members from the worst of COVID.
Children aged 5 to 11 in the North Coast region will be eligible to receive a new, lower-dose formulation of Pfizer’s COVID-19 vaccine from Monday 10 January 2022.
With the dramatic increase in transmission rates due to the now-dominant Omicron strain, Healthy North Coast Chief Executive Officer Julie Sturgess is strongly encouraging parents and guardians to make a booking for children in their care in the coming weeks.
‘We know that vaccination reduces the risk of transmission as well as serious illness and hospitalisation from COVID-19,’ said Ms Sturgess.
‘The North Coast community vaccination rate for those aged 16 and up now stands at 93.6%, and our 12 to 15 year-olds have been eligible to book their COVID vaccination since September 2021.
‘With the strong uptake in our region, we expect that parents and carers are well acquainted with the benefits of vaccination and are ready to extend the same level of protection to our younger community members,’ Ms Sturgess said.
The Australian Technical Advisory Group on Immunisation (ATAGI) recommended vaccination for children aged 5 to 11 years in December 2021, following earlier approval by the Therapeutic Goods Administration.
Approval was based on a careful evaluation of available data to support its safety and efficacy among this age group.
The under-12s Pfizer vaccine is 10μg (0.2mL) or only a third of the recommended 30μg dose administered to people aged 12 and over.
The smaller dose will have an orange-capped vial to differentiate it from the 12 years and older vaccine.
Children under 12 will still receive two doses, though these will be eight weeks apart, unlike the three-week interval for older cohorts.
Health advice is that a longer interval between doses appears to generate a stronger immune response.
‘We’re encouraging any parent or guardian to use the Vaccine Clinic Finder to book an appointment over the coming weeks, while their school-aged children are still on holidays,’ Ms Sturgess said.
‘If you are unable to find a suitable appointment, please check back regularly as more appointments will become available as supply to the region increases.
‘Healthy North Coast is also open to working with other appropriate venues and locations, which may include schools, to expedite the rollout.’
Any parent of guardian who has concerns about the suitability of the vaccination for a child in their care should speak with their GP.

Continue Reading

Latest News

Subscribe for our newsletter!

error: Alert: Content is protected !!